Completed PHASE3 INTERVENTIONAL NCT00293891

A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis

Sponsor: Astellas Pharma Inc

Conditions Psoriasis

Updated 6 times since 2017 Last updated: Dec 19, 2007 Completion: Jan 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00293891, this PHASE3 trial focuses on Psoriasis and remains completed. Sponsored by Astellas Pharma Inc, it has been updated 6 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Inc
Astellas Pharma US, Inc.

Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Birmingham, United States , Calgary, Canada , Columbus, United States , Dallas, United States , Dayton, United States , Denver, United States , Durham, United States , Edmonton, Canada , Houston, United States and 23 more locations